Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
August 10, 2021
Retrospective studies demonstrated reduced COPD exacerbations in T2DM patients on GLP-1RAs, as compared to DPP-4 inhibitors and sulfonylureas [9, 79]
The benefit design comes from the employer, not UHC
The treatment area appears thinner and more defined over time, with results appearing a few months later
You may be eligible if you: Have a BMI over 30, or over 27 with weight-related health concerns Struggle with appetite control or weight loss despite lifestyle changes Are not currently pregnant or breastfeeding Have not had bariatric surgery within the last 18 months Do not have a history of contraindicated conditions such as pancreatitis, medullary thyroid cancer, pancreatitis, or MEN syndrome, or certain kinds of endocrine cancers Are committed to monthly check-ins and physician-guided care *During your consultation, a medical provider will review your health history, lab work, and goals to determine your eligibility for GLP-1 treatment for weight loss
There are also concerns that GLP-1 RAs may significantly increase levels of dabigatran, potentially raising bleeding risk
